Adonis vs Crosby Health
Two Denials & Appeals vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Adonis | Crosby Health | |
|---|---|---|
| Pricing model | Not published · Custom quotes via demo | Contingency (pay from recoveries) · Managed appeals; SaaS license also offered |
| Speed to go live | API connection to EHR, billing, payer portals | Portal-based upload, light integration |
| Automation model | Autonomous agents · agents plus revenue intelligence alerts | Autonomous agents · Apollo LLM drafts and submits appeals |
| Built for | Mid-size groups, Enterprise systems, Billing companies | Mid-size groups, Enterprise systems |
| Security posture | HIPAA | HIPAA |
| Company maturity | 4 yrs (est. 2022) | 4 yrs (est. 2022) |
| Financial backing | $95M+ · Series C | $2.2M+ · Seed |
| Named customers | 5 named | 1 named |
| Published results | No public numbers | Specific numbers public |
| Documented integrations | 5 listed | None documented |
| Third-party validation | None found | None found |
Bottom line
- Pick Adonis if you want AI agents and revenue analytics layered onto your existing EHR and billing stack without replacing it.
- Pick Crosby Health if clinical denials are piling up unworked and you want appeals generated and submitted automatically while paying only from what gets recovered.
Adonis
Revenue intelligence and denial prevention
- Founded
- 2022
- HQ
- New York, NY
- Stage
- Series C
- Raised
- $95M+
What it does
- Real-time revenue intelligence dashboards across the claim lifecycle
- Detects denials, underpayments, and revenue leakage automatically
- AI agents work claims: status checks, appeals, resubmissions
- Prioritized worklists route staff to highest-value tasks
- Alerts on payer behavior changes before revenue impact spreads
- Orchestration layer sits on top of existing billing systems
Where it's strong
- Analytics-first approach surfaces why revenue is leaking, not just that it is, which most billing systems cannot do.
- AI agents now autonomously progress claims, and traction is real: 4x revenue growth in 2025 with Mount Sinai as a flagship customer.
- Works on top of your existing EHR and billing stack rather than replacing it.
What buyers should weigh
- It augments your RCM team rather than replacing it; you still need billers, unlike full-service RCM vendors.
- The company is four years old and scaling fast, so expect some product churn and evolving packaging.
- Value depends on claim volume; small practices may not generate enough data to justify the platform.
Named customers
Mount Sinai Health System · Allied Digestive Health · ApolloMD · Seaview Orthopaedic & Medical Associates · Tend Dental
Integrations
Crosby Health
AI-generated clinical appeals for denied claims
- Founded
- 2022
- HQ
- New York, NY
- Stage
- Seed
- Raised
- $2.2M+
What it does
- Generates clinical appeal letters for denied claims with AI
- Apollo clinical LLM reads up to 300 pages of documentation
- Finds medical necessity evidence inside clinical notes
- Submits appeals through one unified payer submission channel
- Tracks appeal status and payer decisions with notifications
- Supports medical coding review and chart auditing
Where it's strong
- Attacks a problem most providers simply abandon: appealing every denial, including small balances that are uneconomical to work manually.
- Unified payer submission removes the portal-and-fax maze that makes appeals so labor intensive.
- Early users report appealing denials 300% faster than manual processes.
What buyers should weigh
- Very early company: roughly 15 employees, about $3M raised, and only one publicly named customer.
- Appeals-only focus means it recovers lost revenue but does nothing to prevent denials upstream.
- No publicly documented EHR integrations, so verify how clinical documentation actually gets into the platform.
Named customers
EmpowerMe Wellness
Compare against the rest of Denials & Appeals
Deciding between these two?
First Pass tracks Denials & Appeals every week: funding, launches, and what changed since this page was written.